cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.25934/pr00011517
title: Phase I/II study of S49076, a multi-target inhibitor of c-MET, AXL, FGFR in combination with bevacizumab in patients with recurrent glioblastoma multiforme

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.5067/modis/mod21a2.006
title: MOD21A2 MODIS/Terra Land Surface Temperature/3-Band Emissivity 8-Day L3 Global 1km SIN Grid V006
DOI: 10.25934/pr00011518
title: Phase I/II study of oral administration of S49076 given in combination with gefitinib in patients with EGFR mutated advanced non-small-cell lung cancer who have progressed after treatment with EGFR tyrosine kinase inhibitor

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00011519
title: Phase I dose escalation study of oral administration of Pan-Histone Deacetylase (HDAC) inhibitor S 78454 given in combination with a fixed dose infusion of cisplatin in patients with advanced non-keratinising nasopharyngeal carcinoma.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.5067/modis/mod44b.006
title: MOD44B MODIS/Terra Vegetation Continuous Fields Yearly L3 Global 250m SIN Grid V006
DOI: 10.25934/pr00011520
title: An open, 3-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1-amplified or non-amplified estrogen receptor positive metastatic breast cancer. – FINESSE

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00011521
title: Phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with oestrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer.-INES

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00011522
title: A randomized, double-masked, placebo-controlled study of the efficacy of gevokizumab in the treatment of patients with Behçet’s Disease uveitis. EYEGUARD-B

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.5067/modis/mod44w.006
title: MOD44W MODIS/Terra Land Water Mask Derived from MODIS and SRTM L3 Global 250m SIN Grid V006
DOI: 10.25934/pr00011523
title: A safety open-label study of Gevokizumab in the treatment of patients with chronic non-infectious Uveitis disease, an eXtension study. The EYEGUARD-X study.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.5067/modis/modocga.006
title: MODOCGA MODIS/Terra Ocean Reflectance Daily L2G-Lite Global 1km SIN Grid V006
DOI: 10.25934/pr00011524
title: Phase I dose-escalation study of oral administration of the selective Bcl2 inhibitor S55746 in patients with refractory or relapsed Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00011525
title: Phase I dose-escalation study of the orally administrered selective Bcl-2 inhibitor S055746 as monotherapy for the treatment of patients with Acute Myeloid Leukaemia (AML) or high or very high risk Myelodysplastic Syndrome (MDS)

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.5067/modis/modtbga.006
title: MODTBGA MODIS/Terra Thermal Bands Daily L2G-Lite Global 1km SIN Grid V006
DOI: 10.25934/pr00011526
title: Evaluation of the effects of 4 oral dosages of S 44121 versus placebo on cardiac function and NT-proBNP in patients with chronic heart failure and left ventricular dysfunction not treated with a beta-blocker. A 12-week, randomized, double-blind, parallel-group, placebo controlled, international multicentre study

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00011527
title: Evaluation of the anti-arrhythmic effects of 3 oral dosages of S 44121 versus placebo in patients with chronic heart failure and left ventricular systolic dysfunction at risk for ventricular arrhythmia. A 12-week, randomized, double-blind, parallel-group, placebo controlled, international multicentre study.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00011528
title: Efficacy and safety of 3 doses of S 47445 versus placebo in patients with Alzheimer’s disease at mild to moderate stages with depressive symptoms. A 24-week international, multi-centre, randomized, double-blind, placebo-controlled phase II study in monotherapy followed by an optional 28-week extension period in co-administration with donepezil.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.5067/modis/myd09a1.006
title: MYD09A1 MODIS/Aqua Surface Reflectance 8-Day L3 Global 500m SIN Grid V006
DOI: 10.25934/pr00011529
title: Efficacy and safety of S 47445 versus placebo as adjunctive treatment of Major Depressive Disorder in patients with an inadequate response to antidepressant therapy. A randomised, double-blind, placebo controlled international, multicentre study.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00011530
title: Evaluation of the pharmacodynamics, pharmacokinetics and safety of repeated escalating oral doses of S 38844 versus placebo in patients with chronic heart failure and left ventricular systolic dysfunction. A phase II, randomised, double-blind, parallel-group, placebo controlled, international multicentre study

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00011531
title: Efficacy and safety of bumetanide oral liquid formulation in children and adolescents aged from 7 to less than 18 years old with Autism Spectrum Disorder

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.5067/modis/myd09cmg.006
title: MYD09CMG MODIS/Aqua Surface Reflectance Daily L3 Global 0.05Deg CMG V006
DOI: 10.25934/pr00011532
title: Efficacy and safety of bumetanide oral liquid formulation in children aged from 2 to less than 7 years old with Autism Spectrum Disorder.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00011533
title: Phase I dose-escalation study of S 81694 administered intravenously in adult patients with advanced/metastatic solid tumors

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.5067/modis/myd09ga.006
title: MYD09GA MODIS/Aqua Surface Reflectance Daily L2G Global 1kmand 500m SIN Grid V006
DOI: 10.25934/pr00011534
title: Phase I/II trial of S 81694 administered intravenously in combination with paclitaxel to evaluate the safety, pharmacokinetic and efficacy in metastatic breast cancer

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00011535
title: An Open-Label, Dose-escalation, Phase I/IIa Study to Determine the Maximum Tolerated Dose, Recommended Dose, Efficacy, Pharmacokinetics and Pharmacodynamics of the dual VEGFR-FGFR Tyrosine Kinase Inhibitor, E-3810, Given Orally as Single Agent to Patients With Advanced Solid Tumours.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.5067/modis/myd09gq.006
title: MYD09GQ MODIS/Aqua Surface Reflectance Daily L2G Global 250m SIN Grid V006
DOI: 10.25934/pr00011536
title: A randomized, double blind, placebo-controlled, parallel, international multicenter study assessing the efficacy of S066913 in patients with paroxysmal atrial fibrillation Double-blind, International study AssessinG efficacy of S 066913 in paRoxysmal Atrial Fibrillation – IKur inhibitor (DIAGRAF – IKUR) – DIAGRAF-IKur

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00011537
title: Randomized Efficacy and Safety Trial with Oral S 44819 after Recent ischemic cerebral Event. International, multi-centre, randomized, double-blind placebo-controlled phase II study. – RESTORE BRAIN study

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00011538
title: Efficacy and safety of 3 doses of S 38093 (2, 5 and 20 mg/day) versus placebo, in co-administration with donepezil (10 mg/day) in patients with moderate Alzheimer’s Disease. A 24-week international, multi-centre, randomised, double-blind, placebo-controlled phase IIb study.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.5067/modis/myd09q1.006
title: MYD09Q1 MODIS/Aqua Surface Reflectance 8-Day L3 Global 250m SIN Grid V006
DOI: 10.25934/pr00011539
title: A Multicentre, Randomized, Double-blind, Placebo-controlled Dose-finding Study of S62798 in Patients with Intermediate-High Risk Acute Pulmonary Embolism on heparin

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00011541
title: LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

description: The reason for this study is to see if the study drug selpercatinib compared to a standard treatment is effective and safe in participants with rearranged during transfection (RET) fusion-positive non-squamous non-small cell lung cancer (NSCLC) that has spread to other parts of the body. Participants who are assigned to the standard treatment and discontinue due to progressive disease have the option to potentially crossover to selpercatinib.
DOI: 10.5067/modis/myd11_l2.006
title: MYD11_L2 MODIS/Aqua Land Surface Temperature/Emissivity 5-Min L2 Swath 1km V006
DOI: 10.25934/pr00011542
title: Weekly Enteric-Coated Fluoxetine Hydrochloride Versus Daily Fluoxetine or Placebo in the Continuation Treatment of Major Depressive Disorder

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.5067/modis/myd11a1.006
title: MYD11A1 MODIS/Aqua Land Surface Temperature/Emissivity Daily L3 Global 1km SIN Grid V006
DOI: 10.5067/modis/myd11a2.006
title: MYD11A2 MODIS/Aqua Land Surface Temperature/Emissivity 8-Day L3 Global 1km SIN Grid V006
DOI: 10.5067/modis/myd11b1.006
title: MYD11B1 MODIS/Aqua Land Surface Temperature/Emissivity Daily L3 Global 6km SIN Grid V006
DOI: 10.5067/modis/myd11b2.006
title: MYD11B2 MODIS/Aqua Land Surface Temperature/Emissivity 8-day L3 Global 6km SIN Grid V006
DOI: 10.5067/modis/myd11b3.006
title: MYD11B3 MODIS/Aqua Land Surface Temperature/Emissivity Monthly L3 Global 6km SIN Grid V006
DOI: 10.5067/modis/myd11c1.006
title: MYD11C1 MODIS/Aqua Land Surface Temperature/Emissivity Daily L3 Global 0.05Deg CMG V006
DOI: 10.5067/modis/myd11c2.006
title: MYD11C2 MODIS/Aqua Land Surface Temperature/Emissivity 8-Day L3 Global 0.05Deg CMG V006
DOI: 10.5067/modis/myd11c3.006
title: MYD11C3 MODIS/Aqua Land Surface Temperature/Emissivity Monthly L3 Global 0.05Deg CMG V006
DOI: 10.5067/modis/myd13a1.006
title: MYD13A1 MODIS/Aqua Vegetation Indices 16-day L3 Global 500m SIN Grid V006
DOI: 10.5067/modis/myd13a2.006
title: MYD13A2 MODIS/Aqua Vegetation Indices 16-Day L3 Global 1km SIN Grid V006
DOI: 10.5067/modis/myd13a3.006
title: MYD13A3 MODIS/Aqua Vegetation Indices Monthly L3 Global 1km SIN Grid V006
DOI: 10.5067/modis/myd13c1.006
title: MYD13C1 MODIS/Aqua Vegetation Indices 16-Day L3 Global 0.05Deg CMG V006
DOI: 10.5067/modis/myd13c2.006
title: MYD13C2 MODIS/Aqua Vegetation Indices Monthly L3 Global 0.05Deg CMG V006
DOI: 10.5067/modis/myd13q1.006
title: MYD13Q1 MODIS/Aqua Vegetation Indices 16-Day L3 Global 250m SIN Grid V006
DOI: 10.5067/modis/myd14.006
title: MYD14 MODIS/Aqua Thermal Anomalies/Fire 5-Min L2 Swath 1km V006
DOI: 10.5067/modis/myd14a1.006
title: MYD14A1 MODIS/Aqua Thermal Anomalies/Fire Daily L3 Global 1km SIN Grid V006
DOI: 10.5067/modis/myd14a2.006
title: MYD14A2 MODIS/Aqua Thermal Anomalies/Fire 8-Day L3 Global 1km SIN Grid V006
DOI: 10.5067/modis/myd15a2h.006
title: MYD15A2H MODIS/Aqua Leaf Area Index/FPAR 8-Day L4 Global 500m SIN Grid V006
DOI: 10.5067/modis/myd16a2.006
title: MYD16A2 MODIS/Aqua Net Evapotranspiration 8-Day L4 Global 500m SIN Grid V006
DOI: 10.5067/modis/mcd12c1.006
title: MCD12C1 MODIS/Terra+Aqua Land Cover Type Yearly L3 Global 0.05Deg CMG V006
DOI: 10.5067/modis/mcd12q1.006
title: MCD12Q1 MODIS/Terra+Aqua Land Cover Type Yearly L3 Global 500m SIN Grid V006
DOI: 10.5067/modis/mcd12q2.006
title: MCD12Q2 MODIS/Terra+Aqua Land Cover Dynamics Yearly L3 Global 500m SIN Grid V006
DOI: 10.5067/modis/mcd15a2h.006
title: MCD15A2H MODIS/Terra+Aqua Leaf Area Index/FPAR 8-day L4 Global 500m SIN Grid V006
DOI: 10.5067/modis/mcd15a3h.006
title: MCD15A3H MODIS/Terra+Aqua Leaf Area Index/FPAR 4-day L4 Global 500m SIN Grid V006
DOI: 10.5067/modis/mcd18a1.006
title: MODIS/Terra+Aqua Surface Radiation Daily/3-Hour L3 Global 5km SIN Grid V006
DOI: 10.5067/modis/mcd18a2.006
title: MODIS/Terra+Aqua Photosynthetically Active Radiation Daily/3-Hour L3 Global 5km SIN Grid V006
DOI: 10.5067/modis/mcd19a1.006
title: MCD19A1 MODIS/Terra+Aqua Land Surface BRF Daily L2G Global 500m and 1km SIN Grid V006
DOI: 10.5067/modis/mcd19a2.006
title: MCD19A2 MODIS/Terra+Aqua Land Aerosol Optical Depth Daily L2G Global 1km SIN Grid V006